Pulmonary hypertension in heart failure with preserved ejection fraction: A target of phosphodiesterase-5 inhibition in a 1-year study

Circulation

Volumn 124, Issue 2, 2011, Pages 164-174

  Guazzi, Marco ^a   Vicenzi, Marco ^a   Arena, Ross ^b   Guazzi, Maurizio D ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

diastolic heart failure; heart failure; pulmonary hypertension

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO; SILDENAFIL;

ADULT; AGED; ALVEOLAR CAPILLARY GAS CONDUCTANCE; ARTERY RESISTANCE; ARTICLE; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DOUBLE BLIND PROCEDURE; DRUG TARGETING; DYSPNEA; EMOTION; FATIGUE; FEMALE; HEART HEMODYNAMICS; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE RELAXATION; HEART MUSCLE RELAXATION; HEART RIGHT VENTRICLE ENDDIASTOLIC PRESSURE; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE MEAN SYSTOLIC EJECTION RATE; HUMAN; ISOVOLUMIC RELAXATION TIME; LUNG ARTERIOLE RESISTANCE; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; LUNG FLUID; LUNG HEMODYNAMICS; LUNG WEDGE PRESSURE; MALE; MEAN PULMONARY ARTERY PRESSURE; MEAN RIGHT ATRIAL PRESSURE; MEAN WEDGE PULMONARY PRESSURE; PRIORITY JOURNAL; PULMONARY ARTERIAL ELASTANCE; PULMONARY ARTERY DIASTOLIC PRESSURE; PULMONARY ARTERY SYSTOLIC PRESSURE; PULMONARY HYPERTENSION; RESPIRATORY TRACT PARAMETERS; SEPTAL MITRAL ANNULUS VELOCITY; STARLING LAW; SYSTOLIC BLOOD PRESSURE; TRANSPULMONARY GRADIENT; TREATMENT OUTCOME; TRICUSPID ANNULAR SYSTOLIC EXCURSION; WATER CONTENT;

AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PREVALENCE; PURINES; RESPIRATORY FUNCTION TESTS; STROKE VOLUME; SULFONES;

EID: 79960396933     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.983866     Document Type: Article

References (43)

1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-259. (Pubitemid 44079340)
2. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Hauzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355:260-269. (Pubitemid 44088349)
3. Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, Arbustivi E, Recusani F, Gavazzi L. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol. 2001;37: 183-188. (Pubitemid 32051736)
4. Lam CSP, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009;53:1119-1126.
5. Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol. 2009;53:582-588.
6. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC Yang JP, Tang WH. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589-596.
7. Gottlieb SS. The impact of finally publishing a negative study: new conclusions about endothelin antagonists. J Card Fail. 2005;11:21-22. (Pubitemid 40215309)
8. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, Darius H, Schulman K, Zannad F, Handberg-Thurmond E, Harrell FE Jr, Wheeler W, Soler-Soler J, Swedberg K. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997;134:44-54. (Pubitemid 27329022)
9. Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophys-iology and management. Circulation. 2000;102:1718-1723.
10. Guazzi M, Arena R. Pulmonary hypertension with left-sided heart disease. Nat Rev Cardiol. 2010;7:648-59.
11. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, Taylor M, Adams K, Saboninski M, Worcen M, Cohn JN. Combination of isosorbide dinitrate and hydralazine in black with heart failure. N Engl J Med. 2004;351:2049-2057.
12. Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol. 2007;50:2136-2144. (Pubitemid 350117342)
13. Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KV, Semigran MJ. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007;116:1555-1562. (Pubitemid 47511419)
14. Lewis GD. The role of the pulmonary vasculature in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2009;53:1127-1129.
15. Guazzi M. Clinical use of phoshodiesterae-5 inhibitors in chronic heart failure. Circ Heart Fail. 2008;1:272-280.
16. Drake RE, Giesler M, Laine GA, Gabel JC, Hansen TN. Effect of outflow pressure on lung lymph flow in anesthetized sheep. J Appl Physiol. 1985;58:70-76. (Pubitemid 15054380)
17. Oh JK, Hatle L, Tajik AJ, Little WC. Diastolic heart failure can be diagnosed by comprehensive two dimensional and Doppler echocardiog-raphy. J Am Coll Cardiol. 2006;47:500-506. (Pubitemid 43170836)
18. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
19. Chantler PD, Lakatta EG, Najjar SS. Arterial ventricular coupling: mechanistic insights into cardiovascular performance at rest and during exercise. J Appl Physiol. 2008;105:1342-1351.
20. American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med. 1995;152:1107-1136.
21. Hankinson JL, Odenerantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159:179-187. (Pubitemid 29036522)
22. Roughton FJW, Forster FE. Relative importance of diffusion and chemical reaction rate of exchange of gases in human lung, with special reference to true diffusing capacity of blood in the lung capillaries. J Appl Physiol. 1957;11:290-302.
23. Guazzi M, Agostoni P, Guazzi MD. Modulation of alveolar capillary sodium handling as a mechanism of protection of gas transfer by enalapril, and not by losartan, in chronic heart failure. J Am Coll Cardiol. 2001;37:398-406.
24. Pistolesi M, Giuntini C. Assessment of extravascular lung water. Radiol Clin North Am. 1978;16:551-574. (Pubitemid 9105583)
25. Rivas-Gotz C, Khoury DS, Manolios M, Rao L, Kopelen HA, Nagueh SF. Time interval between onset of mitral inflow and onset of early diastolic velocity by tissue Doppler: a novel index of left ventricular relaxation: experimental studies and clinical application. J Am Coll Cardiol. 2003; 42:1463-1470. (Pubitemid 37267291)
26. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise J, Solomon S, Spencer KT, St John Sutton M, Stewart W. American Society of Echocardiography's Nomenclature and Standard Committee: Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography; European Society of Cardiology. Eur J Echocardiogr. 2006;7:79-108.
27. Kaul S, Tei C, Hopkins JM, Shah PM. Assessment of right ventricular function using two-dimensional echocardiography. Am Heart J. 1984; 107:526-531. (Pubitemid 14167729)
28. Guyatt GH, Nogradi S, Halcrows, Singer J, Sullivan MJ, Fallen EL. Development and testing of a new measure of health status for clinical trials in heart failure. J Gen Intern Med. 1989;4:101-107. (Pubitemid 19081188)
29. Maeder MT, Kaye DM. Heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol. 2009;53:905-918.
30. Wang J, Nagueh SF. Current perspectives of cardiac function in patients with diastolic heart failure. Circulation. 2009;119:1146-1157.
31. Hernandez AF, Hammill BG, O'Connor CM, Shulman KA, Curtis LH, Fonarow GC. Clinical effectiveness of beta-blockers in heart failure: findings from OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) registry. J Am Coll Cardiol. 2009;53:184-192.
32. Delgado JF, Conde E, Sánchez V, Lopez-Rios F, Gomez-Sanchez MA, Escribano P, Doleto T, Gomez de la Camara A, Cortina J, S De la Calzada C. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail. 2005;7:1011-1016. (Pubitemid 41443595)
33. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G; for the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148-2157. (Pubitemid 41653106)
34. Olivari MT, Fiorentini C, Polese A, Guazzi MD. Pulmonary hemody-namics and right ventricular function in hypertension. Circulation. 1978; 54:1185-1190. (Pubitemid 8343641)
35. Guazzi MD, De Cesare N, Fiorentini C, Galli C, Montorsi P, Pepi M, Tamborini G. Pulmonary vascular supersensitivity to catecholamines in systemic high blood pressure. J Am Coll Cardiol. 1986;8:1137-1144. (Pubitemid 16009101)
36. Guazzi MD, Alimento M, Berti M, Fiorentini C, Galli C, Tamborini G. Enhanced hypoxic pulmonary vasoconstriction in hypertension. Circulation. 1989;79:337-343. (Pubitemid 19055504)
37. Guazzi MD, Polese A, Bartorelli A, Loaldi A, Fiorentini C. Evidence of a shared mechanism of vasoconstriction in pulmonary and systemic circulation in hypertension: a possible role of intracellular calcium. Circulation. 1982; 66:881-886. (Pubitemid 12015076)
38. Melenovsky V, Al-Hiti H, Kazdova L, Jabor A, Syrovatka P, Malek I, Kettner J, Kautzner J. Transpulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafil. J Am Coll Cardiol. 2009;54:595-600
39. Nagendran J, Archer SL, Soliman D, Gurtu V, Mondgil R, Haromi A, St Aubin C, Webster L, Rebeyka M, Ross DB, Light PE, Dyck JR, Michelakis ED. Phosphodiesterase type 5 is highly expressed in hyper-trophied human right ventricle and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007;116:238-248. (Pubitemid 47196559)
40. Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry and clinical status in patients with stable systolic heart failure: results of a 1-year prospective, randomized, placebo-controlled study. Circ Heart Fail. 2011; 4:8-17.
41. Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Pur-kayastha D, Lacourcière Y, Hippler SE, Fields H, Naqvi TZ, Mulvagh SL, Arnold JM, Thomas JD, Zile MR, Aurigemma GP; Valsartan In Diastolic Dysfunction (VALIDD) Investigators. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet. 2007;369: 2079-2087. (Pubitemid 46935945)
42. Hughes JMD. Pulmonary complications of heart disease. In: Mason RJ, Broaddus VC, Murray JF, Nadel JA, eds. Textbook of Respiratory Medicine. Philadelphia, PA: Elsevier Saunders; 2005:2200-2222.
43. Garcia JGN, Malik AB. Pulmonary circulation and regulation of fluid balance. In: Mason RJ, Broaddus VC, Murray JF, Nadel JA, eds. Textbook of Respiratory Medicine. Philadelphia, PA: Elsevier Saunders; 2005:136-171.